国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
International Medicine and Health Guidance News
2015年
20期
3058-3060
,共3页
黄芪注射液%糖皮质激素%狼疮性肾炎%疗效%免疫功能
黃芪註射液%糖皮質激素%狼瘡性腎炎%療效%免疫功能
황기주사액%당피질격소%랑창성신염%료효%면역공능
Astragalus injection%Glucocorticoid%Lupus nephritis%Efficacy%Immune function
目的 探讨黄芪注射液结合糖皮质激素治疗狼疮性肾炎的疗效及对患者免疫功能的影响.方法 选取94例狼疮性肾炎患者为研究对象,根据其就诊顺序分成联合组(A组,n=47)和对照组(B组,n=47)两组.B组予以单纯糖皮质激素疗法,A组采用糖皮质激素+黄芪注射液疗法.比较两组患者治疗前后24 h尿蛋白、血肌酐(SCr)、血尿素氮(BUN)等生化指标变化情况,记录其CD3、CD4及CD8等免疫指标变化差异.结果 ①治疗后,A组患者24h尿蛋白及BUN指标分别为(1.0±0.2)g和(6.1±2.0) mmol/L,显著低于B组的(1.9±0.3)g和(8.6±3.4)mmol/L,两组比较差异具有统计学意义(P＜0.05);B组患者SCr水平为(73.1±8.0)μmol/L,显著低于A组患者的(83.4±10.6)μmol/L,差异具有统计学意义(P＜0.05);②治疗后,两组患者CD3及CD4等免疫功能指标同治疗前比较差异无统计学意义(P＞0.05);B组患者CD8检测结果为(38.9±12.5),显著高于A组患者的(33.6±12.9),差异具有统计学意义(P＜0.05).结论 对狼疮性肾炎患者予以糖皮质激素联合黄芪注射液疗法,疗效确切,能改善其免疫功能,值得临床推广.
目的 探討黃芪註射液結閤糖皮質激素治療狼瘡性腎炎的療效及對患者免疫功能的影響.方法 選取94例狼瘡性腎炎患者為研究對象,根據其就診順序分成聯閤組(A組,n=47)和對照組(B組,n=47)兩組.B組予以單純糖皮質激素療法,A組採用糖皮質激素+黃芪註射液療法.比較兩組患者治療前後24 h尿蛋白、血肌酐(SCr)、血尿素氮(BUN)等生化指標變化情況,記錄其CD3、CD4及CD8等免疫指標變化差異.結果 ①治療後,A組患者24h尿蛋白及BUN指標分彆為(1.0±0.2)g和(6.1±2.0) mmol/L,顯著低于B組的(1.9±0.3)g和(8.6±3.4)mmol/L,兩組比較差異具有統計學意義(P＜0.05);B組患者SCr水平為(73.1±8.0)μmol/L,顯著低于A組患者的(83.4±10.6)μmol/L,差異具有統計學意義(P＜0.05);②治療後,兩組患者CD3及CD4等免疫功能指標同治療前比較差異無統計學意義(P＞0.05);B組患者CD8檢測結果為(38.9±12.5),顯著高于A組患者的(33.6±12.9),差異具有統計學意義(P＜0.05).結論 對狼瘡性腎炎患者予以糖皮質激素聯閤黃芪註射液療法,療效確切,能改善其免疫功能,值得臨床推廣.
목적 탐토황기주사액결합당피질격소치료랑창성신염적료효급대환자면역공능적영향.방법 선취94례랑창성신염환자위연구대상,근거기취진순서분성연합조(A조,n=47)화대조조(B조,n=47)량조.B조여이단순당피질격소요법,A조채용당피질격소+황기주사액요법.비교량조환자치료전후24 h뇨단백、혈기항(SCr)、혈뇨소담(BUN)등생화지표변화정황,기록기CD3、CD4급CD8등면역지표변화차이.결과 ①치료후,A조환자24h뇨단백급BUN지표분별위(1.0±0.2)g화(6.1±2.0) mmol/L,현저저우B조적(1.9±0.3)g화(8.6±3.4)mmol/L,량조비교차이구유통계학의의(P＜0.05);B조환자SCr수평위(73.1±8.0)μmol/L,현저저우A조환자적(83.4±10.6)μmol/L,차이구유통계학의의(P＜0.05);②치료후,량조환자CD3급CD4등면역공능지표동치료전비교차이무통계학의의(P＞0.05);B조환자CD8검측결과위(38.9±12.5),현저고우A조환자적(33.6±12.9),차이구유통계학의의(P＜0.05).결론 대랑창성신염환자여이당피질격소연합황기주사액요법,료효학절,능개선기면역공능,치득림상추엄.
Objective To explore clinical efficacy of Astragalus injection combined with glucocorticoid in the treatment of lupus nephritis and its effect on immune function of patients.Methods 94 patients with lupus nephritis were divided into combined group (group A, n=47) and control group (group B, n=47) according to the order of treatment.Group B was treated with glucocorticoid, while group A was treated with glucocorticoid and Astragalus injection.Compared the changes of 24 h urinary protein, serum creatinine (SCr), blood urea nitrogen (BUN) and other biochemical indicators before and after treatment of two groups.Recorded the changes of CD3, CD4, CD8 and other immune indices.Results ① After treatment, 24 h urinary protein and BUN of group A were (1.0±0.2)g and (6.1±2.0)mmol/L, significantly lower than (1.9±0.3)g and (8.6±3.4)mmol/L of group B, SCr of group A was (83.4±10.6)μmol/L, significantly higher than (73.1±8.0)μmol/L of group B, with statistically significant differences between two groups (P＜0.05).② There were statistically significant differences in CD3, CD4 before and after treatment in both two groups (P＞0.05);CD8 of group B was (38.9±12.5), significantly higher than (33.6±12.9) of group A, with statistically significant difference between two groups (P＜0.05).Conclusion Astragalus injection combined with glucocorticoid has definite curative effect in the treatment of lupus nephritis, which can improve immune function of patients, worthy of clinical promotion.
